Journal
ACS NANO
Volume 10, Issue 3, Pages 3469-3477Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.5b07576
Keywords
cancer; FDG-PET; CT; gold nanoparticles; metabolic-based imaging
Categories
Funding
- Research and Development Chief Scientist Kamin grant [49544]
- Israel Cancer Research Fund (ICRF)
- Israel Science Foundation [749/14]
- Ministry of Science, Technology Space, Israel
Ask authors/readers for more resources
One of the main limitations of the highly used cancer imaging technique, PET-CT, is its inability to distinguish between cancerous lesions and post treatment inflammatory conditions. The reason for this lack of specificity is that [F-18]FDG-PET is based on increased glucose metabolic activity, which characterizes both cancerous tissues and inflammatory cells. To overcome this limitation, we developed a nanoparticle-based approach, utilizing glucose-functionalized gold nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our approach demonstrates specific tumor targeting and has successfully distinguished between cancer and inflammatory processes in a combined tumor-inflammation mouse model, due to dissimilarities in angiogenesis occurring under different pathologic conditions. This study provides a set of capabilities in cancer detection, staging and follow-up, and can be applicable to a wide range of cancers that exhibit high metabolic activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available